In the treatment of colorectal cancer, a phase IIa clinical trial included 103 newly diagnosed colorectal adenocarcinoma patients who, after surgical resection and adjuvant radiotherapy (including TMZ chemotherapy), received injections of the MUC1 peptide vaccine along with TMZ adjuvant chemotherapy. Here, MUC1 is linked to colorectal adenocarcinoma.